Pulmonary Cell News Volume 12.26 | Jul 06 2023

    By
    Jamie Kang
    -
    0
    10







    2023-07-06 | PULCN 12.26


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 12.26 – 6 July, 2023
    TOP STORY

    SUMOylation of Rho-Associated Protein Kinase 2 Induces Goblet Cell Metaplasia in Allergic Airways

    Researchers explored the potential role and underlying mechanism of protein SUMOylation-mediated goblet cell metaplasia.
    [Nature Communications]

    Full Article
    Register for the 2nd Niche-Epithelial Stem Cell Interactions in Lung Health and Disease Conference.
    PUBLICATIONSRanked by the impact factor of the journal

    Mesenchymal Stromal Cells Facilitate Resolution of Pulmonary Fibrosis by miR-29c and miR-129 Intercellular Transfer

    The authors evaluated the potency of mesenchymal stromal cell secretome components to prevent pulmonary fibrosis development and facilitate fibrosis resolution.
    [Experimental & Molecular Medicine]

    Full Article

    AAV9-Tspyl2 Gene Therapy Retards Bleomycin-Induced Pulmonary Fibrosis by Modulating Downstream TGF-β Signaling in Mice

    Investigators focused on cell division autoantigen-1, which was significantly decreased in human idiopathic pulmonary fibrosis (IPF), in a mouse model of bleomycin-induced PF, and in transforming growth factor (TGF-β)-challenged lung fibroblasts.
    [Cell Death & Disease]

    Full Article

    NRF1 Knockdown Alleviates Lipopolysaccharide-Induced Pulmonary Inflammatory Injury by Upregulating DKK3 and Inhibiting the GSK-3β/β-Catenin Pathway

    Human embryonic lung WI-38 and MRC-5 cells were treated with lipopolysaccharide to induce inflammatory injury of neonatal pneumonia in vitro.
    [Clinical And Experimental Immunology]

    Abstract
    Graphical Abstract

    Peptide-Functionalized Electrospun Meshes for the Physiological Cultivation of Pulmonary Alveolar Capillary Barrier Models in a 3D-Printed Micro-Bioreactor

    An in vitro pulmonary alveolar capillary barrier model was developed that closely mimicked physiological functions by combining a synthetic biofunctionalized nanofibrous membrane system with a novel three-dimensional (3D)-printed bioreactor.
    [ACS Biomaterials Science & Engineering]

    Full ArticleGraphical Abstract

    Schisandrin A Regulates the Nrf2 Signaling Pathway and Inhibits NLRP3 Inflammasome Activation To Interfere with Pyroptosis in a Mouse Model of COPD

    Researchers studied the pharmacological effect of Schisandrin A (SchA) on airway inflammation induced by cigarette smoke and explored the therapeutic mechanism of SchA in COPD model mice.
    [European Journal Of Medical Research]

    Full Article

    UHRF1 Is a Mediator of KRAS Driven Oncogenesis in Lung Adenocarcinoma

    To identify KRAS-specific vulnerabilities in lung cancer, scientists performed RNAi screens in primary spheroids derived from a Kras mutant mouse lung cancer model and discovered an epigenetic regulator Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1).
    [Nature Communications]

    Full Article

    MLK4 Promotes Glucose Metabolism in Lung Adenocarcinoma through CREB-Mediated Activation of Phosphoenolpyruvate Carboxykinase and Is Regulated by KLF5

    Investigators showed that MLK4 was overexpressed in a significant subset of lung adenocarcinoma, associated with a worse prognosis, and exerted an oncogenic function in vitro and in vivo.
    [Oncogenesis]

    Full Article

    The Role of TOP2A in Immunotherapy and Vasculogenic Mimicry in Non-Small Cell Lung Cancer and Its Potential Mechanism

    Scientists investigated the role of type IIA topoisomerase (TOP2A) in proliferation, skeleton regulation, motility, and vasculogenic mimicry production in NSCLC and its mechanisms by using bioinformatics tools and molecular biology experiments.
    [Scientific Reports]

    Full Article
    Scientific resources to support your organoids research. Learn More!
    REVIEWS

    Role of Early Growth Response 1 in Inflammation-Associated Lung Diseases

    Early growth response 1 (EGR1) may be a target for early and effective intervention in these inflammation-associated lung diseases.
    [American Journal Of Physiology-Lung Cellular And Molecular Physiology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Bristol Myers Squibb Receives European Commission Approval for Opdivo
    (Nivolumab) with Chemotherapy As Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

    The decision was based on results from the Phase III CheckMate -816 trial, in which three cycles of Opdivo with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival and pathologic complete response.
    [Bristol Myers Squibb]

    Press Release
    FEATURED EVENT

    Angiogenesis and Angiostability in Development, Disease, and Engineered Tissues

    July 30 – August 4, 2023
    Newport, Rhode Island, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Immunology, Lung Fibrosis

    University of Oxford – Oxford, England, United Kingdom

    Postdoctoral Research Fellow – Rheumatology

    Boston University – Boston, Massachusetts, United States

    Postdoctoral Researcher – Inflammatory Conditions

    Maynooth University – Maynooth, Ireland

    Medical Director – Pulmonary Hypertension

    University of Texas at Austin – Austin, Texas, United States

    Assistant Professor – Clinical Medicine, Pulmonary

    University of Miami – Miami, Florida, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter